Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Operations (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cash from Operations for 8 consecutive years, with 15378000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 1.97% to 15378000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 95252000.0, a 75.93% decrease, with the full-year FY2024 number at 59550000.0, changed 0.19% from a year prior.
  • Cash from Operations was 15378000.0 for Q3 2025 at Whitehawk Therapeutics, up from 52957000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 10563000.0 in Q1 2021 to a low of 52957000.0 in Q2 2025.
  • A 5-year average of 14288157.89 and a median of 12428000.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 368.11% in 2021, then plummeted 478.32% in 2025.
  • Whitehawk Therapeutics' Cash from Operations stood at 12428000.0 in 2021, then grew by 9.0% to 11310000.0 in 2022, then rose by 14.73% to 9644000.0 in 2023, then crashed by 56.09% to 15053000.0 in 2024, then fell by 2.16% to 15378000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Cash from Operations are 15378000.0 (Q3 2025), 52957000.0 (Q2 2025), and 11864000.0 (Q1 2025).